CKDの進行におけるRAASi,MRA,FGF-23は,通常の疑わしいものですか?
Giuseppe Cianciolo1, Michele Provenzano2, Lilio Hu3
1Nephrology, Dialysis and Kidney Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Minerva urology and nephrology
|September 5, 2025
まとめ
慢性腎疾患 (CKD) の管理は,アルドステロンの突破と,レニン=アニオテンシン=アルドステロンシステムの (RAAS) 阻害効果に影響を与えるFGF23による課題に直面しています. SGLT-2阻害剤やMRAのような新しい治療法では,これらの障害を克服し,よりよいCKDの結果を出すことが期待されています.
科学分野:
- 腎臓科
- 心血管医学
- 内分泌学
背景:
- 慢性腎臓病 (CKD) は,全般的な健康に影響を与え,心血管疾患のリスクと死亡率を高めます.
- レニン・アニオテンシン・アルドステロン系 (RAAS) 阻害は標準的な治療法ですが,限界があります.
- アルドステロンの突破とFGF23の上昇は,CKDにおけるRAAS阻害の有効性を低下させる.
研究 の 目的:
- アルドステロン突破とFGF23を中心に,CKDの進行メカニズムを解明する.
- CKDとその合併症の管理のための新しい治療戦略を探求する.
- RAASのブロック効果を高め,心血管疾患のリスクを軽減するためのアプローチを特定する.
主な方法:
- CKDの病理生理学と治療に関する現在の文献のレビュー.
- アルドステロン突破,FGF23,アクチニンのCKD進行における役割の分析
- SGLT-2阻害剤,GLP-1受容体アゴニスト,MRAを含む新興治療法の評価
主要な成果:
- アルドステロンのブレークスルーとFGF23はRAAS抑制を妨害し,CKDと心血管疾患のアウトカムを悪化させる.
- SGLT-2阻害剤,GLP-1RAおよびMRAのような新しい薬剤は,これらの制限を克服する可能性を秘めています.
- これらの治療はFGF23のレベルを低下させ,アルドステロンの調節を改善します.
結論:
- アルドステロン突破とFGF23を理解することは,CKDの効果的な管理に不可欠です.
- 新興治療法では,CKDの進行と心血管疾患のリスクを大幅に改善することが期待されています.
- これらの経路をターゲットにすることで 慢性腎臓病患者の治療を最適化する 新しい道が開けます
関連する概念動画
01:25Chronic Kidney Disease I: Introduction
65
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
65
01:28Chronic Kidney Disease III: Interprofessional Care
77
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
77
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:28Glomerular Filtration Rate and its Regulation
3.3K
The Glomerular Filtration Rate (GFR) is a measure of kidney function, reflecting the volume of filtrate formed per minute in the kidneys. On average, GFR is approximately 125 mL/min in males and 105 mL/min in females. Maintaining a relatively constant GFR is essential for the kidneys to effectively regulate body fluid homeostasis and maintain extracellular stability.
GFR regulation involves two primary intrinsic controls: the myogenic and tubuloglomerular feedback mechanisms.
The myogenic...
GFR regulation involves two primary intrinsic controls: the myogenic and tubuloglomerular feedback mechanisms.
The myogenic...
3.3K
01:25Antihypertensive Drugs: Direct Renin Inhibitors
817
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
817
01:13Introduction to Urinary System
4.1K
The urinary system consists of two kidneys, two ureters, the urinary bladder, and the urethra.
The kidneys are bean-shaped organs located in the retroperitoneal space, on either side of the vertebral column, between the T12 and L3 vertebrae. They are partially protected by the rib cage and surrounded by perirenal fat, which provides cushioning. They are responsible for urine formation and play critical roles in regulating blood pressure, electrolyte levels, and hormone production. The ureters...
The kidneys are bean-shaped organs located in the retroperitoneal space, on either side of the vertebral column, between the T12 and L3 vertebrae. They are partially protected by the rib cage and surrounded by perirenal fat, which provides cushioning. They are responsible for urine formation and play critical roles in regulating blood pressure, electrolyte levels, and hormone production. The ureters...
4.1K